ALEX RAREY: Open Payments
NPI 1720842982 · PUTNAM, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$848 in 7 payments from 6 companies in 2025. Trend: 2023 $0 · 2024 $125 · 2025 $848
Food & beverage: $848
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 2 | $251 |
| Teva Pharmaceuticals USA, Inc. | 1 | $129 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $125 |
| Luye Pharma (USA) Ltd. | 1 | $120 |
| Neurocrine BioSciences, Inc. | 1 | $119 |
| Otsuka America Pharmaceutical, Inc. | 1 | $104 |
Products named: COBENFY, UZEDY, CAPLYTA, ERZOFRI EXTENDED-RELEASE, INGREZZA, ABILIFY MAINTENA.
Industry payments across CT — which companies pay providers there.
